“What About the Implant, Doc?” Appraising Various Formulations of Buprenorphine
The Carlat Addiction Treatment Report, Volume 8, Number 5, July 2020
https://www.thecarlatreport.com/newsletter-issue/catr8n5/
Issue Links: Learning Objectives | Editorial Information
Topics: Buprenorphine | extended-release | Medication | Medication adherence | Opioid epidemic | Opioid Use Disorder | Pharmacology | safety | Side Effects
Edmund S. Higgins, MD.
Clinical Associate Professor of Psychiatry and Family Medicine, MUSC, Charleston, SC.
Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Buprenorphine can be administered via intravenous, transdermal, sublingual, buccal, and implanted formulations. We appraise the evidence for various formulations and suggest certain populations for which certain formulations may be a better choice.
You can't view details of this content, please login or buy subscription here